• QTTB

Q32 Bio: Oppenheimer slashes price target on mixed trial results

Oppenheimer reduced Q32 Bio Inc's price target to $20 after mixed Phase 2 trial results for Bempikibart, while retaining an Outperform rating amidst significant stock decline.